Short description
Nkarta Therapeutics is a developer of cell engineering platform created to build the next generation of cell therapies.
Description
Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.
While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited to a few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
Last funding
No Way
Sign in for full access
Total funding
$$43214321
Sign in for full access
Location
South San Francisco, California, United States, North America
Founded on
January 1, 2015
Exited on
July 10, 2020
Went public on
July 10, 2020
Stock symbol
NKTX
Non-profit?
No
Acquired?
No
Employees count
101-250
Revenue range
$7890 - 12340
Sign in for full access
Investors
Nopepepe, Cannot Access, No Way, No Way, Noaccess, Noaccess, Cannot Access, No Way, Noway Youcantaccess, No Way, Blurry Noaccess, Noway Youcantaccess, Noway Youcantaccess, Nopepepe, Nopepepe, No Way, Nopepepe
Sign in for full access
Founders
Dario Campana